Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3043% below fair value
$3.06+0.04 (+1.32%)
Close on Nov 19, 2026Market cap $246.55MP/E 13.3Yield –
Protalix BioTherapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Protalix BioTherapeutics's pe ratio was 13.6× on Nov 11, 2026, against 38.8× a year earlier. Over the last 4 years it ranged from 0.9× to 155.0×, with a median of 18.1×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 13.6× | −31.4 |
| 2025 | Dec 31, 2025 | 45.0× | +23.4 |
| 2024 | Jul 31, 2024 | 21.6× | −14.0 |
| 2023 | Dec 29, 2023 | 35.6× | +34.3 |
| 2017 | Jan 31, 2017 | 1.3× | +0.4 |
| 2016 | Dec 30, 2016 | 1.0× | – |
See a number that looks wrong?